AI ASSISTANT
Ask DrugCentral
Explore drug properties, targets, and indications with answers grounded in DrugCentral.
Powered by DrugCentral + retrieval-augmented AIYour question
Ask in your own words. Each question is answered independently.
Explore sample questions
Select a question to fill the editor, then ask it or make it your own.
DrugCentral answer
Your answer will appear here. Open linked drug cards in a new tab to explore the source details.
About Ask DrugCentral
Ask DrugCentral helps you explore drug properties, biological targets, and indications using natural language. Sample questions offer starting points, and linked drug cards let you check the underlying records.
General architecture
- Ask a questionThe browser sends your question to the same-origin Django chat API.
- Retrieve and generateThe API forwards the question to the configured DrugCentral retrieval-augmented generation (RAG) service, which returns an AI-generated answer.
- Explore the answerThe app resolves cited drug-card names and displays the answer with links to drug records.
Using the assistant
Each request is independent; previous questions are not sent as conversation history. You can edit a sample before submitting, retry a failed request, or switch back to normal search. Drug links open in a new tab so your question and answer stay available.
Answers may contain mistakes or omit information. Verify details against DrugCentral records and original sources.
AI can make mistakes. Verify answers against the original sources before relying on them.
hydroquinone 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| 3282 | 123-31-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
skin depigmentation agent
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| kinase-safety-class | ACVR2A,ACVR2B,ACVRL1,AKT2,AKT3,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK1,CDK4,CDK5,CDK9,CHEK1,CSF1R,DDR1,DYRK1B,EIF2AK3,EPHB4,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP2K6,MAP3K1,MAP3K10,MAP3K14,MAP3K21,MAP3K7,MAP4K1,MAP4K3,MAPK10,MAPK7,MAPK9,MAPKAPK2,MARK4,MTOR,NTRK2,PDK1,PDK2,PDK4,PDPK1,PIK3CA,PIK3CB,PIK3CD,PIM2,PRKCD,PRKDC,SGK1,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1,ULK2,ZAP70 | 65 | |||
| kinase-selectivity-class | ACVR2A,ACVR2B,ACVRL1,AXL,BMX,CAMK2B,CAMK2D,CDK4,CDK9,DDR1,DYRK1B,EPHB4,GRK2,MAP2K3,MAP2K6,MAP3K21,MAPK7,MARK4,PIK3CB,PIK3CD,PRKDC,SIK2,SIK3,STK33,SYK,TEK,TGFBR1,TTK,ULK1 | 29 | |||
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| Jan. 18, 2002 | FDA | GALDERMA LABS LP |
FDA Adverse Event Reporting System (Female)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Squamous cell carcinoma of skin | 194.70 | 31.61 | 36 | 705 | 7413 | 90620293 |
| Skin atrophy | 108.31 | 31.61 | 21 | 720 | 5508 | 90622198 |
| Neoplasm skin | 74.37 | 31.61 | 14 | 727 | 3128 | 90624578 |
| Ochronosis | 61.41 | 31.61 | 7 | 734 | 42 | 90627664 |
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
| MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
|---|---|---|---|---|---|---|
| Squamous cell carcinoma of skin | 175.27 | 31.63 | 36 | 638 | 17167 | 110571458 |
| Skin atrophy | 110.90 | 31.63 | 21 | 653 | 6543 | 110582082 |
| Ochronosis | 80.67 | 31.63 | 9 | 665 | 61 | 110588564 |
| Neoplasm skin | 78.22 | 31.63 | 14 | 660 | 3190 | 110585435 |
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | D11AX11 | DERMATOLOGICALS OTHER DERMATOLOGICAL PREPARATIONS OTHER DERMATOLOGICAL PREPARATIONS Other dermatologicals |
| MeSH PA | D000975 | Antioxidants |
| MeSH PA | D009153 | Mutagens |
| MeSH PA | D009676 | Noxae |
| MeSH PA | D011837 | Radiation-Protective Agents |
| MeSH PA | D020011 | Protective Agents |
| FDA MoA | N0000175850 | Melanin Synthesis Inhibitors |
| FDA PE | N0000175851 | Depigmenting Activity |
| FDA EPC | N0000175854 | Melanin Synthesis Inhibitor |
| CHEBI has role | CHEBI:22586 | antioxidant |
| CHEBI has role | CHEBI:23357 | cofactor |
| CHEBI has role | CHEBI:50903 | carcinogenic agent |
| CHEBI has role | CHEBI:75771 | mouse metabolite |
| CHEBI has role | CHEBI:76967 | human xenobiotic metabolite |
| CHEBI has role | CHEBI:76971 | <em>Escherichia coli</em> metabolite |
| CHEBI has role | CHEBI:85046 | skin lightening agent |
Related Drugs by ATC class:
D11AX Other dermatologicals 20 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Discoloration of skin | indication | 3253007 | |
| Chloasma | indication | 36209000 | |
| Facial Hyperpigmentation | indication | ||
| Sunburn | contraindication | 23346002 | |
| Eczema | contraindication | 43116000 | |
| Telangiectasia disorder | contraindication | 247479008 | |
| Pregnancy, function | contraindication | 289908002 | |
| Adrenal cortical hypofunction | contraindication | 386584007 | DOID:10493 |
| Atrophoderma | contraindication | 399979006 | |
| Peripheral vascular disease | contraindication | 400047006 | |
| Breastfeeding (mother) | contraindication | 413712001 | |
| Denuded skin | contraindication | 418242004 |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.26 | acidic |
| pKa2 | 11.59 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Carbonic anhydrase 2 | Enzyme | Ki | 7.05 | CHEMBL | |||||
| Carbonic anhydrase 1 | Enzyme | Ki | 4.97 | CHEMBL | |||||
| Carbonic anhydrase 4 | Enzyme | Ki | 4.97 | CHEMBL | |||||
| Carbonic anhydrase 9 | Enzyme | Ki | 4.49 | CHEMBL | |||||
| Carbonic anhydrase 12 | Enzyme | Ki | 5.11 | CHEMBL | |||||
| Carbonic anhydrase 5A, mitochondrial | Enzyme | Ki | 4.85 | CHEMBL | |||||
| Carbonic anhydrase 5B, mitochondrial | Enzyme | Ki | 4.90 | CHEMBL | |||||
| Tyrosinase | Enzyme | IC50 | 4.82 | CHEMBL | |||||
| Carbonic anhydrase 3 | Enzyme | Ki | 5.09 | CHEMBL | |||||
| Carbonic anhydrase 14 | Enzyme | Ki | 4.38 | CHEMBL | |||||
| Carbonic anhydrase 13 | Enzyme | Ki | 4.13 | CHEMBL | |||||
| Acetylcholinesterase | Enzyme | Ki | 8.91 | CHEMBL | |||||
| Polyphenol oxidase 2 | Enzyme | IC50 | 5.01 | CHEMBL | |||||
| Carbonic anhydrase 15 | Enzyme | Ki | 4.97 | CHEMBL | |||||
| Carbonic anhydrase | Enzyme | Ki | 5.23 | CHEMBL |
External reference:
| ID | Source |
|---|---|
| XV74C1N1AE | UNII |
| 4018886 | VUID |
| N0000147180 | NUI |
| D00073 | KEGG_DRUG |
| 4018886 | VANDF |
| C0020306 | UMLSCUI |
| CHEBI:17594 | CHEBI |
| HQE | PDB_CHEM_ID |
| CHEMBL537 | ChEMBL_ID |
| 785 | PUBCHEM_CID |
| DB09526 | DRUGBANK_ID |
| C031927 | MESH_SUPPLEMENTAL_RECORD_UI |
| 5509 | RXNORM |
| 1507 | MMSL |
| 4849 | MMSL |
| 002019 | NDDF |
| 387422001 | SNOMEDCT_US |
| 74583006 | SNOMEDCT_US |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| TRI-LUMA | HUMAN PRESCRIPTION DRUG LABEL | 3 | 0299-5950 | CREAM | 40 mg | TOPICAL | NDA | 24 sections |
| hydroquinone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 10135-724 | CREAM | 40 mg | TOPICAL | unapproved drug other | 19 sections |
| Skin LighteningRodan Fields | HUMAN OTC DRUG LABEL | 1 | 14222-1615 | LIQUID | 2 mL | TOPICAL | OTC monograph not final | 8 sections |
| Skin Beautifying Milk | HUMAN OTC DRUG LABEL | 1 | 16708-001 | CREAM | 0.02 g | TOPICAL | OTC monograph not final | 11 sections |
| Medicated Fade Creme with Sunscreen | HUMAN OTC DRUG LABEL | 2 | 16708-002 | CREAM | 0.02 g | TOPICAL | OTC monograph not final | 10 sections |
| Advanced Lightning | HUMAN OTC DRUG LABEL | 2 | 24623-042 | CREAM | 0.02 g | TOPICAL | OTC MONOGRAPH NOT FINAL | 11 sections |
| Hydroquinone cream | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24689-101 | CREAM | 40 mg | TOPICAL | unapproved drug other | 11 sections |
| Hydro-Q | HUMAN PRESCRIPTION DRUG LABEL | 1 | 30815-0040 | GEL | 40 mg | TOPICAL | UNAPPROVED DRUG OTHER | 17 sections |
| HYDROQUINONE 4% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42192-151 | CREAM | 40 mg | TOPICAL | unapproved drug other | 21 sections |
| Hydroquinone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42582-700 | CREAM | 40 mg | TOPICAL | UNAPPROVED DRUG OTHER | 22 sections |
| ZO Skin Health Pigment Control plus Brightening Creme Hydroquinone plus Vitamin C | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42851-035 | EMULSION | 0.04 mg | TOPICAL | unapproved drug other | 5 sections |
| ZO Skin Health Pigment Control Plus Blending Creme Hydroquinone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42851-036 | EMULSION | 0.04 g | TOPICAL | unapproved drug other | 5 sections |
| ZO Skin Health Pigment Control Creme Hydroquinone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 42851-037 | EMULSION | 40 mg | TOPICAL | unapproved drug other | 5 sections |
| ZO Skin Health Pigment Control Creme Hydroquinone | HUMAN OTC DRUG LABEL | 1 | 42851-038 | LOTION | 20 mg | TOPICAL | OTC monograph not final | 13 sections |
| ZO Skin Health Pigment Control Plus Blending Creme Hydroquinone | HUMAN OTC DRUG LABEL | 1 | 42851-039 | LOTION | 20 mg | TOPICAL | OTC monograph not final | 13 sections |
| I-MAX LIGHTENING 5 | HUMAN OTC DRUG LABEL | 1 | 42952-201 | CREAM | 2 g | TOPICAL | OTC monograph not final | 12 sections |
| I-MAX LIGHTENING L | HUMAN OTC DRUG LABEL | 1 | 42952-203 | CREAM | 2 g | TOPICAL | OTC monograph not final | 11 sections |
| Hydroquinone | HUMAN PRESCRIPTION DRUG LABEL | 1 | 45865-214 | CREAM | 40 mg | TOPICAL | unapproved drug other | 21 sections |
| LIGHT THE WAY | HUMAN OTC DRUG LABEL | 1 | 49520-201 | LOTION | 2 g | TOPICAL | OTC monograph not final | 14 sections |
| Teatrical Pro-Aclarant Skin Lightening | HUMAN OTC DRUG LABEL | 1 | 50066-072 | CREAM | 20 mg | TOPICAL | OTC MONOGRAPH NOT FINAL | 15 sections |
| Hydroquinone 4% | HUMAN PRESCRIPTION DRUG LABEL | 1 | 50405-800 | CREAM | 40 mg | TOPICAL | UNAPPROVED DRUG OTHER | 21 sections |
| Rejuvaderm medispa fading | HUMAN OTC DRUG LABEL | 1 | 51325-300 | LOTION | 1.20 mL | TOPICAL | OTC monograph not final | 9 sections |
| Porcelana Day Skin Lightening | HUMAN OTC DRUG LABEL | 2 | 51545-110 | CREAM | 0.02 g | TOPICAL | OTC monograph not final | 10 sections |
| PIONA | HUMAN OTC DRUG LABEL | 1 | 52927-200 | LOTION | 1.95 1 | TOPICAL | OTC monograph not final | 8 sections |
| Total White Brightening | HUMAN OTC DRUG LABEL | 2 | 53218-001 | LOTION | 9.46 mg | TOPICAL | OTC monograph not final | 12 sections |
| Total White Brightening | HUMAN OTC DRUG LABEL | 2 | 53218-002 | CREAM | 2 g | TOPICAL | OTC monograph not final | 12 sections |
| BRIGHTENLIGHTENING | HUMAN OTC DRUG LABEL | 1 | 54272-301 | GEL | 2 g | TOPICAL | OTC monograph not final | 13 sections |
| Dark Spot Lightening Cream | HUMAN OTC DRUG LABEL | 1 | 56152-4002 | CREAM | 2 g | TOPICAL | OTC monograph not final | 8 sections |
| Divine Derrier Skin Bleaching cream | HUMAN OTC DRUG LABEL | 1 | 56152-4004 | CREAM | 2 g | TOPICAL | OTC monograph not final | 8 sections |
| Ultra Glow Fadewith Aloe Vera | HUMAN OTC DRUG LABEL | 2 | 58318-002 | CREAM | 1 g | TOPICAL | OTC monograph not final | 9 sections |